Publication Topic

Gentry R, Thompson CM, Franzen A, Salley J, Albertini R, Lu K, Greene T. 2020. Using mechanistic information to support evidence integration and synthesis: A case study with inhaled formaldehyde and leukemia. Crit Rev Toxicol 50(10):885–918; doi: 10.1080/10408444.2020.1854678. PMID: 33538218.

Saldanha G, Ording AG, Bylsma LC, Darvalics B, Solis D, Tang JY, Sorensen HT, Fryzek J. 2020. High frequency basal cell carcinoma (BCC) in Danish patients: Prevalence and consistency. J Eur Acad Dermatol Venereol 34(10):e646-e648; doi: 10.1111/jdv.16512. PMID: 32314479.

Levin-Sparenberg E, Bylsma LC, Lowe K, Sangare L, Fryzek JP, Alexander DD. 2020. A systematic literature review and meta-analysis describing the prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer. Gastroenterol Res 13(5):184–198; doi: 10.14740/gr1167. PMID: 33224365.

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. 2020. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. Curr Med Res Opin 36(9):1519–1527; doi: 10.1080/03007995.2020.1801403. PMID: 32715807.

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. 2020. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 28(9):4413–4424; doi: 10.1007/s00520-020-05295-2. PMID: 31919669.

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478; doi: 10.1038/s41375-020-0770-8. PMID: 32094465.

Dronin-Fenton D, Dalvi T, Movva N, Pedersen I, Hansen H, Fryzek J, Mellemgaard A, Rasmussen T, et al. PD-L1 expression and survival in stage III unresectable non-small cell lung cancer patients in Denmark. Abstract #2865, European Society for Medical Oncology (ESMO), Virtual, August 2020.

Lafranconi M, Budinsky R, Corey L, Haws L, Klapacz J, Chappell G, Golden R. Exposure to 1,4-dioxane above the metabolic saturation threshold induces a mitogenic key element in the mouse liver cancer mode of action. Abstract #1505. Society of Toxicology 59th Annual Meeting, Virtual, 2020.

Jackson C, Choi J, Khalafallah AM, Price C, Bettegowda C, Lim M, et al. 2020. A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. J Neuro-Oncol 148(3):419–431; doi: 10.1007/s11060-020-03556-y. PMID: 32562247.

Elbeddini A, Hooda N, Gazarin M, Webster P, McMillan J. 2020. Irinotecan-associated dysarthria in patients with pancreatic cancer: A single site experience. Am J Case Rep 21:e924058; doi: 10.12659/AJCR.924058. PMID: 32594093.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Jena A, et al. 2020. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. J Med Econ 23(6):581-592; doi: 10.1080/13696998.2020.1730123. PMID: 32063100.

Botros D, Dux H, Price C, Khalafallah AM, Mukherjee D. 2020. Assessing the efficacy of repeat resections in recurrent glioblastoma: A systematic review. Neurosurg Rev 44:1259–1271; doi: 10.1007/s10143-020-01331-1. PMID: 32533385.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. Budget impact of improving adherence to colorectal cancer screening. Abstract PCN148, ISPOR 2020.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. The impact of increasing mt-sDNA use among colorectal cancer screeners in a US employer population. Abstract PCN145, ISPOR 2020.

Cohen S, Reichert H, Kansal AR, Chung KC. Improved efficiency of cancer screening with multi-cancer early detection test. International Society for Pharmacoeconomics and Outcomes Research, Inc. (ISPOR) Virtual Conference, May 2020.

Menon N, Leslie TF, Frankenfeld CL. 2020. Cancer-related diagnostic and treatment capabilities of hospitals in the context of racial residential segregation. Public Health 182(May):95–101; https://doi.org/10.1016/j.puhe.2020.02.004. PMID: 32213360.

Stalbovskaya V, Wasserman E, Fryzek J, Bylsma L, Sirulnik A. NRG1 fusion-driven cancers: A systematic literature review and meta-analysis. Abstract, Annual Meeting of the American Society of Clinical Oncology, May 2020.

Frankenfeld CL, Menon N, Leslie TF. 2020. Racial disparities in colorectal cancer time-to-treatment and survival time for colorectal tumors and diagnosing hospital cancer-related diagnostic and treatment capabilities. Cancer Epidemiol 65(Apr):101684; doi: 10.1016/j.canep.2020.101684. PMID: 32058312.

Jensen IS, Hathway J, Cyr PL, Gauden D, Gardiner P. 2020. Cost–consequence analysis of ¹⁸F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362. PMID: 32341772.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al.  Consequences of increasing mt-sDNA utilization among colorectal cancer screening strategies from a payer perspective. American Society of Preventative Oncology 44th Annual ASPO Conference, 2020.